Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in HFpEF Inflammation Pilot
NCT05330013Phase 2Withdrawn
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jun 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by National Heart, Lung, and Blood Institute. Planned start Jun 2022; status: withdrawn.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05330013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330013.